1-22. (canceled)
23. An information managing apparatus, comprising:
registration means for registering information to be distributed;
setting means for setting printable dates of the information registered by said registration means;
distribution means for distributing the information registered by said registration means to a print control apparatus; and
notification means for notifying the printable dates set by setting means to a communication terminal of a user utilizing said print control apparatus.
24. The apparatus according to claim 23, further comprising determination means for determining whether or not the information registered by said registration means has been printed,
wherein said notification means notifies the printable dates according to a determination result of the determination by said determination means.
25. The apparatus according to claim 24, further comprising deleting means for deleting the information registered by said registration means when said determination means determines that the information has been printed.
26. The apparatus according to claim 23, further comprising determination means for determining whether or not the printable dates are within a predetermined date range,
wherein said notification means notifies the printable dates according to a determination result by said determination means.
27. The apparatus according to claim 23, where a notification by said notification means is performed periodically.
28. The apparatus according to claim 23, further comprising storing means for storing a table for managing information associated with the user.
29. The apparatus according to claim 28, wherein the information associated with the user includes at least one of a name, a telephone number and a notification destination.
30. An information managing method, comprising:
a registration step of registering information to be distributed;
a setting step of setting printable dates of the information registered in said registration step;
a distribution step of distributing the information registered in said registration step to a print control apparatus; and
a notification step of notifying the printable dates set in setting step to a communication terminal of a user utilizing said print control apparatus.
31. The method according to claim 30, further comprising a determination step of determining whether or not the information registered in said registration step has been printed,
wherein said notification step notifies the printable dates according to a determination result by said determination step.
32. The method according to claim 31, further comprising a deleting step of deleting the information registered in said registration step when said determination step determines that the information has been printed.
33. The method according to claim 30, further comprising a determination step of determining whether or not the printable dates are within a predetermined date range,
wherein said notification step notifies the printable dates according to a determination result by said determination step.
34. The method according to claim 30, wherein a notification by said notification step is performed periodically.
35. The method according to claim 30, further comprising a storing step of storing a table for managing information associated with the user.
36. The method according to claim 35, wherein the information associated with the user includes at least one of a name, a telephone number and a notification destination.
37. A computer executable program stored on a computer readable medium for making a computer implement a control method of an information management apparatus, the program comprising:
a registration step of registering information to be distributed;
a setting step of setting printable dates of the information registered in said registration step;
a distribution step of distributing the information registered in said registration step to a print control apparatus; and
a notification step of notifying the printable dates set in setting step to a communication terminal of a user utilizing said print control apparatus.
38. The program according to claim 37, further comprising a determination step of determining whether or not the information registered in said registration step has been printed,
wherein said notification step notifies the printable dates according to a determination result by said determination step.
39. The program according to claim 38, further comprising a deleting step of deleting the information registered in said registration step when said determination step determines that the information has been printed.
40. The program according to claim 37, further comprising a determination step of determining whether or not the printable dates are within a predetermined date range,
wherein said notification step notifies the printable dates according to a determination result of said determination step.
41. The program according to claim 37, wherein a notification in said notification step is performed periodically.
42. The program according to claim 37, further comprising a storing step of storing a table for managing information associated with the user.
43. The program according to claim 42, wherein the information associated with the user includes at least one of a name, a telephone number and a notification destination.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An oral pharmaceutical composition for controlled release and prolonged absorption of at least one active principle in the gastrointestinal tract, wherein the composition comprises:
a plurality of particles having a diameter of 50 to 1000 microns, wherein the particles comprise at least one active principle and excipients, wherein the particles are individually coated with a coating composition; and wherein said coating composition comprises at least one film-forming polymer which is insoluble in the fluids of the intestinal tract, at least one nitrogenous polymer, and at least one plasticizer; and
a continuous external phase of excipients comprising:
a polyelectrolytic hydrophilic polymer selected from the group consisting of polyelectrolytic acrylic polymers, polyelectrolytic cellulose polymers, polyelectrolytic polysaccharides polymers, and mixtures thereof, wherein the polyelectrolytic hydrophilic polymer is capable of gelling or crosslinking and is present in a proportion of 60 to 90% by weight on a dry basis with respect to the total mass of the continuous external phase;
a neutral hydrophilic polymer selected from the group consisting of hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), and mixtures thereof, and wherein the neutral hydophilic polymer is present in a proportion of 5 to 40% by weight on a dry basis with respect to the total mass of the continuous external phase; and
a gelling or crosslinking additive having a cation with a valency of two or more present in the proportion of 1 to 5% by weight on a dry basis with respect to the total mass of the continuous external phase; and
wherein a mixture of said plurality of particles and of said continuous external phase of excipients spontaneously forms, in the presence of water in a dissolution test, a macroscopic solid gel composite in less than 30 minutes.
2. The oral pharmaceutical composition of claim 1, wherein said one film-forming polymer is present in a proportion of 50 to 90% by weight on a dry basis with respect to the total mass of the coating composition and is a non water soluble cellulose-based compound;
wherein said nitrogenous polymer is present in a proportion of 2 to 25% by weight on a dry basis with respect to the total mass of the coating composition and is selected from the group consisting of: polyacrylamide, poly-N-vinylamide, poly-N-vinyllactam, polyvinylpyrrolidone and mixtures thereof; and
wherein said plasticizer is present in a proportion of 2 to 20% by weight on a dry basis with respect to the total mass of the coating composition and is selected from the group consisting of: glycerol esters, phthalates, citrates, sebacates, esters of cetyl alcohol, castor oil, and mixtures thereof.
3. The oral pharmaceutical composition of claim 2, wherein said film forming polymer is selected from the group consisting of: ethyl cellulose, cellulose acetate, and mixtures thereof.
4. The oral pharmaceutical composition of claim 2, wherein said coating composition further comprises at least one surface-active or lubricating agent that is present in a proportion of 2 to 20% by weight on a dry basis with respect to the total mass of the coating composition.
5. The oral pharmaceutical composition of claim 4, wherein said surface-active or lubricating agent selected from the group consisting of: anionic surfactants, alkali metals, alkaline earth metal salts of fatty acids, nonionic surfactants, polyoxyethylenated sorbitan esters, polyoxyethylenated castor oil-based compounds, stearates, stearic acid, oleic acid, calcium stearate, aluminium stearate, zinc stearate, stearylfumarates, and mixtures thereof.
6. The oral pharmaceutical composition of claim 2, wherein the film-forming polymer is ethylcellulose and is present in a proportion of 50 to 80% by weight on a dry basis with respect to the total mass of the coating composition, wherein the nitrogenous polymer is polyvinylpyrrolidone and is present in a proportion of 5 to 15% by weight on a dry basis with respect to the total mass of the coating composition, wherein the plasticizer is castor oil and is present in a proportion of 4 to 15% by weight on a dry basis with respect to the total mass of the coating composition, and wherein the surface-active or lubricating agent is magnesium stearate and is present in a proportion of 4 to 15% by weight on a dry basis with respect to the total mass of the coating composition.
7. The oral pharmaceutical composition of claim 1, wherein said gelling or crosslinking additive is a calcium based compound.
8. The oral pharmaceutical composition of claim 7, wherein said gelling or crosslinking additive is calcium acetate.
9. The oral pharmaceutical composition of claim 1, wherein the at least one polyelectrolytic hydrophilic polymer is alginate, wherein the at least one neutral hydrophilic polymer is HPMC, and wherein the gelling or crosslinking additive is calcium acetate.
10. The oral pharmaceutical composition of claim 1, wherein the at least one polyelectrolytic hydrophilic polymer capable of gelling or crosslinking is alginate and is present in a proportion of 70 to 90% by weight on a dry basis with respect to the total mass of the continuous external phase; wherein the at least one neutral hydrophilic polymer is HPMC and is present in a proportion of 10 to 30% by weight on a dry basis with respect to the total mass of the continuous external phase; and wherein the gelling or crosslinking additive is calcium acetate and is present in a proportion of 2 to 4% by weight on a dry basis with respect to the total mass of the continuous external phase.
11. The oral pharmaceutical composition of claim 1, wherein said composition exhibits an in vitro dissolution curve in a dissolution test such that the time to release 20% of the active principle is greater than or equal to 1.5 hours and such that the dissolution curve has a sigmoidal appearance where the point on the dissolution curve where the tangent passes through the origin without cutting the curve has an abscissa greater than or equal to one hour.
12. The oral pharmaceutical composition of claim 1, wherein the at least one neutral hydrophilic polymer has a viscosity \u03b7 at 25\xb0 C. of 10,000 or more mPas at a concentration of 2% and according to the conditions set by US pharmacopeia 2208.
13. The oral pharmaceutical composition of claim 1, wherein the continuous external phase is present in a proportion from 50% to 80% by weight on a dry basis with respect to the total mass of the composition, and wherein the plurality of particles are present in a proportion from 20 to 50% by weight on a dry basis with respect to the total mass of the composition.
14. The oral pharmaceutical composition of claim 1, wherein the composition is in a pulverulent form and the spontaneous formation of a continuous external phase of excipients occurs after the composition is orally ingested.
15. The oral pharmaceutical composition of claim 14, wherein the pulverulent composition is present in a gelatin capsule, and wherein the continuous external phase and plurality of particles spontaneously forms a cohesive solid in the presence of water that maintains its cohesion in an in vitro dissolution test for at least 3 hours.
16. The oral pharmaceutical composition of claim 1, wherein the continuous external phase and plurality of particles are present in a tablet form such that when the tablet is orally ingested, the continuous external phase and plurality of particles spontaneously forms a cohesive solid.
17. The oral pharmaceutical composition of claim 1, wherein the active principle is selected from the group consisting of: antiulcer drugs, antidiabetics, anticoagulants, antithrombics, hypolipemics, antiarrhythmics, vasodilators, antianginals, antihypertensives, vasoprotectants, fertility promoters, uterine labor inducers and inhibitors, contraceptives, antibiotics, antifungals, antivirals, antineoplastics, antiinflammatories, analgesics, antiepileptics, antiparkinsonians, neuroleptics, hypnotics, anxiolytics, psychostimulants, antimigraines, antidepressants, antitussives, antihistaminics, antiallergics, metformin, pentoxyfylline, prazosin, diltiazem, ketoprofen, metoprolol, captopril, atenolol, salbutamol, ranitidine, quinidine, perindopril, morphine, verapamil and mixtures thereof.
18. The oral pharmaceutical composition of claim 1, wherein the active principle is present in a proportion of at most 40% by weight on a dry basis with respect to the total mass of the plurality of particles.
19. The oral pharmaceutical composition of claim 1, wherein the coating composition further comprises:
2 to 20% of a surface-active or lubricating agent selected from the group consisting of: anionic surfactants, alkali metals, alkaline earth metal salts of fatty acids, nonionic surfactants, polyoxyethylenated sorbitan esters, polyoxyethylenated castor oil, stearates, stearic acid, oleic acid, calcium stearate, aluminium stearate, zinc stearate, stearylfumarates, and mixtures thereof.
20. The oral pharmaceutical composition of claim 1, wherein the coating composition further comprises the following compounds by weight on a dry basis with respect to the total mass of the coating composition:
50-80% ethylcellulose, as film-forming polymer,
5-15% polyvinylpyrrolidone, as nitrogenous polymer,
4-15% castor oil, as plasticizer, and
4-15% magnesium stearate, as lubricating agent;
wherein the continuous external phase comprises the following compounds by weight on a dry basis with respect to the total mass of the continuous external phase:
60-90% alginate, as polyelectrolytic hydrophilic polymer,
20-50% HPMC, as neutral hydrophilic polymer, and
2-4% calcium acetate.
21. The oral pharmaceutical composition of claim 1, wherein the at least one nitrogenous polymer is selected from the group consisting of poly-N-vinylamide or vinyllactam, and the at least one plasticizer is selected from the group consisting of glycerol esters and esters of cetyl alcohol.